KBC Group
EGRX

KBC Group’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

KBC Group’s Portfolio EGRX Stock Details EGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-933
Closed -$26K – 1529
2023
Q1 		$26K Hold
933
– – ﹤0.01% 1478
2022
Q4 		$27K Hold
933
– – ﹤0.01% 1485
2022
Q3 		$25K Hold
933
– – ﹤0.01% 1496
2022
Q2 		$41K Buy
+933
New +$42.9K ﹤0.01% 1456
2020
Q2 		– Sell
-504
Closed -$23K – 1327
2020
Q1 		$23K Sell
504
-14,618
-97% -$734K ﹤0.01% 1245
2019
Q4 		$909K Hold
15,122
– – 0.01% 926
2019
Q3 		$855K Buy
15,122
+12,100
+400% +$680K 0.01% 923
2019
Q2 		$168K Buy
+3,022
New +$158K ﹤0.01% 1246
2018
Q4 		– Sell
-17,877
Closed -$1.24M – 1385
2018
Q3 		$1.24M Buy
+17,877
New +$1.36M 0.01% 850

Other funds holding EGRX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

KBC Group's EGRX Position: Q2 2023 in Review

KBC Group sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q2 2023, closing a stake of 933 shares — an estimated $26K sold.

KBC Group first reported a position in EGRX in Q3 2018 and held it in 9 quarters. The position peaked at $1.24M in Q3 2018. 126 funds tracked by Wall St. Rank hold EGRX as of Q2 2023.

  • KBC Group reported no remaining Eagle Pharmaceuticals, Inc. position as of Q2 2023 after selling out during the quarter.
  • KBC Group sold 933 Eagle Pharmaceuticals, Inc. shares in Q2 2023, an estimated $26K.
  • KBC Group first reported a position in Eagle Pharmaceuticals, Inc. in Q3 2018 and held it in 9 quarters.
  • KBC Group's Eagle Pharmaceuticals, Inc. position peaked at $1.24M in Q3 2018.
  • 126 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q2 2023.

Based on KBC Group's 13F filing for Q2 2023, filed 28 Jul 2023.